Viewing affirmative mentions of binding of IL2: interleukin 2 (Homo sapiens)

Full-text article links are indicated by after the article reference.

Document Target Regulator Anatomy Sentence
Adibzadeh et al. (1992)IL-2lip-IL-2LAK cellsThese results suggest that lip-IL-2 can interact with activated T cells and LAK cells in the same way as free IL-2, but that it is much less efficient at activating LAK-cell precursors.
Tanaka et al. (1987)IL 2-bindingIL 2It is conceivable that IL 2 exerts its effect through its interaction with these novel IL 2-binding molecules in SKW 6-4 cells.
Duprez et al. (1992)IL2IL2T lymphocytesIL2 binds to high-affinity IL2 receptors on the surface of T lymphocytes, mediates cell growth, and is internalized.
Mayer et al. (1985)IL 2IL 2B cellThus, it appears that IL 2 does have a role in B cell maturation mediated, in part, by IL 2 binding to the IL 2 receptor present on certain B cells.
Baroja and Ceuppens (1987)IL-2IL-2T-cellsPrecise measurement of IL-2 production in vitro is hampered by binding of IL-2 to IL-2 receptors on activated T-cells which results in IL-2 consumption.
Horst and Flad (1987)interleukin 2interleukin 2Corticosteroid-interleukin 2 interactions: inhibition of binding of interleukin 2 to interleukin 2 receptors.
Ennen et al. (1989)IL 2IL 2monocytesThe priming of monocytes by IL 2 was dependent on the interaction of IL 2 with the monocytic IL 2 receptor, as shown by inhibition experiments with anti-IL 2 receptor monoclonal antibodies.
Smith (2006)IL2IL2Consequently, they then hypothesized that perhaps the IL2-reactive mAb functioned to actually increase biological activity of endogenous IL2 via the formation of immune complexes with IL2, thereby preserving and promoting IL2 activity.
Smith (2006)IL2IL2The structure of IL2 bound to the three chains of the IL2 receptor and how signaling occurs.
Torsella et al. (1992)TCGFTCGFT-cellsAn example of biological transduction, analyzed in this report, is the triggering of T-cell proliferation by the binding of T-cell growth factor (TCGF) to specific TCGF-binding sites on responsive T-cells.
Ennen et al. (1991)IL 2IL 2monocytesThe priming of monocytes by IL 2 was dependent on the interaction of IL 2 with the monocytic IL 2 receptor as shown by inhibition experiments with anti IL 2 R monoclonal antibody.
Lorberboum-Galski et al. (1988)IL2IL2-PE40IL2-PE40 is a powerful reagent for studying IL2 receptor interactions and for analyzing pathways of the immune response and its regulation.
Moreau et al. (1995)IL-2IL-2Characterization of a monoclonal antibody directed against the NH2 terminal area of interleukin-2 (IL-2) and inhibiting specifically the binding of IL-2 to IL-2 receptor beta chain (IL-2R beta).
Oh-Ishi et al. (1989)IL-2-bindingIL-2suppressor T cellsThe role of interleukin-2 (IL-2) in the activation of suppressor T cells was investigated using the monoclonal antibody anti-Tac, which blocks the binding of IL-2 to the 55-kDa IL-2-binding peptide.
Dreno et al. (1989)IL-2IL-2skinFrom the knowledge, for some of these antibodies, of the amino-acid regions they recognize on the IL-2 molecule, it is inferred that the skin antigen shares with IL-2 at least two overlapping epitopes located in the 33-54 amino-acid region of IL-2, a region that has been shown to be involved in the binding of IL-2 to the IL-2-receptor (IL-2-R) 55 kD chain.
Mills et al. (1990)IL2RIL2T lymphocytesInteraction of interleukin 2 (IL2) with its high affinity membrane receptor complex (IL2R) is sufficient to induce proliferation of T lymphocytes.
Oh-Ishi et al. (1988)IL-2IL-2suppressor T cellsThe role of interleukin 2 (IL-2) in the activation of suppressor T cells was investigated by using the monoclonal antibody anti-Tac, which blocks the binding of IL-2 to the 55-kDa peptide of the high-affinity IL-2 receptor.
Bubeník et al. (1987)IL-2IL-2 moleculeThe present study was performed to localize in the IL-2 molecule the active site responsible for interaction with the IL-2 receptor.
Balashova et al. (1991)IL-2LNKB-2 monoclonal antibodyThe minimal IL-2 fragment which can still bind to LNKB-2 monoclonal antibody is -Leu70-Asn71-Leu72-.
Boni et al. (2001)rhIL-2DMPC SUVsSUVsIn the initial step, rhIL-2 rapidly bound to the DMPC SUVs.
Deckert and Legay (1999)IL-2-solubleIgGIn each experiment two successive interactions were monitored: the direct binding of Simulect to an anti-human IgG antibody, followed by the direct binding of IL-2-soluble receptor to the preformed anti-human IgG antibody/Simulect complex.
Tsudo et al. (1983)TCGF receptorAnti-Tac monoclonal antibodyT-cellAnti-Tac monoclonal antibody, which blocks the membrane binding and action of human T-cell growth factor (TCGF), is strongly proposed to recognize TCGF receptor.
Jordan et al. (2003)interleukin-2streptavidinlymphocyteWe have established a lymphocyte activation assay that utilizes fluorescein isothiocyanate (FITC)-streptavidin bound to recombinant biotinylated human interleukin-2 (IL-2).
Mehta et al. (1986)BCGF-12IL 2B cellsBCGF-12 kd receptors on activated B cells have been shown to be distinct form those interacting with IL 2.
Taki et al. (1989)IL-2IL-2The b-IL-2 bound to both low and high affinity IL-2Rs, but the binding to the latter was more intense.
Mills et al. (1990)interleukin 2affinity membrane receptor complexT lymphocytesInteraction of interleukin 2 (IL2) with its high affinity membrane receptor complex (IL2R) is sufficient to induce proliferation of T lymphocytes.
Legrès et al. (1995)interleukin-2human alpha 2-macroglobulinEvidence for the binding of a biologically active interleukin-2 to human alpha 2-macroglobulin.
Ghyka et al. (1992)IL-2interferonleukocyteIntralesional human leukocyte interferon treatment alone or associated with IL-2 in non-AIDS related Kaposi's sarcoma.
Naglieri et al. (1998)interleukin-24-epirubicinStandard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
Moreau et al. (1995)IL-2TS1 alphaalpha cellsMAb 16F11/alpha selectively blocks the IL-2 binding to TS1 alpha cells.
Osheroff et al. (1988)IL-2IgGThe purified IgG of 6A12 is also shown to bind to a purified soluble recombinant p55 subunit of the IL-2 receptor.
Pandolfi et al. (1984)interleukin-2anti-Tac monoclonal antibodyIn addition, these cells were negative with the anti-Tac monoclonal antibody that appears to recognize the receptor for interleukin-2.
Hakimi et al. (1987)IL-2IL-2T-cellThe binding of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) on human T-cells is a key regulatory event which is absolutely required for T-cell-mediated immune responses.
Robb and Kutny (1987)IL 2Tac proteinThe Tac protein is one of at least two glycoproteins known to bind the growth and differentiation factor interleukin 2 (IL 2).
Robb and Kutny (1987)IL 2soluble Tac proteinCompetitive binding studies indicated that the soluble Tac protein retained an ability to bind IL 2 with a low affinity (Kd of 11.1 nM).
Bich-Thuy et al. (1987)IL 2IL 2Because these stimulatory effects of IL 2 occurred in the absence of detectable Tac+ cells, the possibility that IL 2 might be initially interacting with an IL 2 binding protein distinct from the Tac protein was studied.
Kasakura et al. (1984)IL 2anti-TacT cellMonoclonal anti-Tac, that has been suggested to recognize the receptor for human IL 2, was highly inhibitory to the T cell response to the phenyl-Sepharose preparations of BF (IL 2-free).
Theander et al. (1988)IL-2IL-2lymphocytesFurthermore, treatment of phytohemagglutinin-stimulated lymphocytes with AP and ELA resulted in inhibition of binding of intact IL-2 to IL-2 receptors on the stimulated lymphocytes.
Hakimi et al. (1987)IL-2Rinterleukin-2T-cellThe binding of interleukin-2 (IL-2) to the IL-2 receptor (IL-2R) on human T-cells is a key regulatory event which is absolutely required for T-cell-mediated immune responses.
Hakimi et al. (1987)IL-2RIL-2This immunosorbent receptor assay offers a simple and rapid method for studying the binding of IL-2 to human IL-2R.
Moro et al. (1990)LAKIL2Therapeutic combinations combining IL2 associated with LAK or of TIL have been evaluated in some private studies.
Plumas et al. (1991)IL2R p55 subunitIL2eosinophilsCross-linking studies on enriched eosinophils showed one 64-75-kDa band, consisting of IL2 (15 kDa) cross-linked to the IL2R p55 subunit.
Karlsson and Nässberger (1991)interleukin-2interleukin-2T-lymphocytesProliferation of T-lymphocytes is induced by interleukin-2 binding to the interleukin-2 receptor.
Mikha?lova et al. (1999)interleukin-2Fab[Isolation, crystallization, and preliminary x-ray study of a Fab fragment of monoclonal antibody against human interleukin-2 and its complex with antigenic peptide].
Rickert et al. (2005)interleukin-2alpha receptorThe structure of interleukin-2 complexed with its alpha receptor.
Rickert et al. (2005)IL-2common gamma chain (gammac) receptor subunitsInterleukin-2 (IL-2) is an immunoregulatory cytokine that binds sequentially to the alpha (IL-2Ralpha), beta (IL-2Rbeta), and common gamma chain (gammac) receptor subunits.
Adamovic et al. (2008)IL2IL2Association study of IL2/IL21 and FcgRIIa: significant association with the IL2/IL21 region in Scandinavian coeliac disease families.
Adamovic et al. (2008)IL2FcgRIIaAssociation study of IL2/IL21 and FcgRIIa: significant association with the IL2/IL21 region in Scandinavian coeliac disease families.
Malka et al. (2008)IL2gamma cHeteromeric complex formation of IL2-Rbeta or IL-9Ralpha with gamma c is also observed in the absence of ligand (15-30%).
Legrès et al. (1995)IL-2alpha 2M-MAOur results show that native and alpha 2M-MA are able to bind 125I-rhIL-2, with binding occurring only with the latter in a covalent manner, whereas the labeled cytokine is proteolyzed when incubated with alpha 2M-entrapped chymotrypsin.
Legrès et al. (1995)IL-2alpha 2M-MAThe degradation of uncomplexed 125I-rhIL-2 has also been observed in the presence of trypsin, whereas 125I-rhIL-2 bound to alpha 2M-MA is protected.
Shibuya et al. (1994)p56lckinterleukin-2We have shown previously that the interleukin-2 receptor beta-chain interacts both physically and functionally with a Src family member, p56lck, and that p56lck activation leads to induction of the c-fos gene.
Searle et al. (2000)interleukin-2interleukin-2amniotic fluidHuman amniotic fluid lacks interleukin-2 and interleukin-15 but can interact with the beta-chain of the interleukin-2 receptor.
Fallon et al. (2000)IL-2termed 2D1bloodAn interleukin-2 (IL-2) variant containing adjacent point mutations (L18M/L19S, termed 2D1) displaying binding affinity to the heterotrimeric IL-2 receptor similar to that of wild-type IL-2 (WT) had been previously found to surprisingly exhibit increased bioactivity in a peripheral blood lymphocyte proliferation assay.
Reiher et al. (1986)IL-2interleukin 2A region of homology has been found between the envelope (env) protein of the acquired immunodeficiency syndrome (AIDS) virus and a portion of interleukin 2 (IL-2) that purportedly binds to the IL-2 receptor.
Watson et al. (1988)IL2-bindingIL2If IL2 signal transduction involves binding to a surface heterodimeric receptor for IL2, it is argued that FD.huIL2R-2 cells contain an IL2 receptor complex of murine p70 and human p55 IL2-binding proteins.
Miedel et al. (1988)interleukin-2interleukin-2Based on assignment of the disulfide bonds, a structural model of the interleukin-2 receptor for interleukin-2 binding is proposed.
Vazquez et al. (1991)IL-4IL-2This suggests that cAMP and IL-4 directly interact with IL-2 signaling.
Eljaafari et al. (1995)p56lckinterleukin 2lymphocyteInteraction of the interleukin 2 receptor (IL-2R) beta chain with the lymphocyte-specific protein tyrosine kinase (PTK), p56lck, has led to the speculation that p56lck participates in growth signal transduction.
Podwi?ska et al. (1995)IL-2IL-2T cellThese findings suggest that sIL-2R may be bound to IL-2 and in this way would lead to weakening of T cell function and of resistance against Treponema pallidum infection.
Burton et al. (1990)IL-2ICAM-1Taken together with our previous observations, the present studies suggest that ICAM-1 is in proximity and interacts physically with the high-affinity IL-2 receptor.
Moreau et al. (1995)IL-2RIL-2Epitope of mAb 3H9 is localized between residues 30 and 54 and does not affect the binding of IL-2 to IL-2R alpha.
Cheng et al. (2000)IL-2IL-2OBJECTIVES: To establish a novel bioassay method for quantitative analysis of human IL-2 based on the specific binding of Interleukin-2 receptor alpha subunit (IL-2R alpha) with IL-2.
Suminami et al. (1998)IL-2IL-2We have previously reported that human carcinoma cell lines are inhibited in growth by exogenous IL-2, which binds to the IL-2 receptor beta (IL-2Rbeta) chain ubiquitously expressed on the surface of tumor cells.
Reem et al. (1989)TNF-alphaIL-2thymocytesOur observations suggest that TNF-alpha interacts with IL-2 and with another factor(s) which is induced in the course of activation by concanavalin A, since the immunosuppressant drug cyclosporin A-, which inhibits thymocyte activation, prevents the effect of TNF-alpha on thymocytes activated with concanavalin A, whereas anti-Tac, which prevents the binding of IL-2 to its receptor without affecting the production of IL-2 or the expression of IL-2-specific mRNA, inhibits proliferation only partially.
Caligiuri et al. (1990)IL-2IL-2This strongly suggests that additional structural or functional components are involved in generating the proliferative response following the binding of IL-2 to the high affinity heterodimeric form of the IL-2 receptor.
Heuser et al. (2004)HRS3-scFv-Fc-IL-2CD30To stimulate locally the anti-tumour immunity in Hodgkin's disease, we generated an anti-CD30-antibody-interleukin-2 fusion protein (HRS3-scFv-Fc-IL-2) that binds to CD30 constitutively expressed on H/RS cells.
Hatakeyama et al. (1989)IL-2IL-2Interleukin-2 (IL-2) binds to two distinct receptor molecules, the IL-2 receptor alpha (IL-2R alpha, p55) chain and the newly identified IL-2 receptor beta (IL-2R beta, p70-75) chain.
Beadling and Smith (2002)IL-2RIL-2The subsequent interaction of IL-2 with the IL-2Rs then stimulated blastic transformation and progression through G1 and into the S phase of the cell cycle, followed by mitosis [16].
Jacques et al. (1987)IL-2Tac antigenThe results obtained led us to conclude that the soluble IL-2R binds IL-2 with a dissociation constant (KD = 30 nM) identical to that found for the binding of IL-2 to low affinity cell-surface IL-2R (Tac antigen).
Paliogianni et al. (1993)IL-2 geneNF-ATBoth Dex and CsA inhibited the binding of transcription factors AP-1 and NF-AT, but not of NF-kB and OCT-1/OAF, to their corresponding sites on the IL-2 gene promoter.
Lissoni et al. (1994)IL-2interferon alphaRecently, it has been demonstrated that IL-2 given subcutaneously in association with interferon alpha (IFN) may determine a response rate in RCC comparable to that obtained with an intravenous route of administration, but with a lower toxicity.
Hansson et al. (1987)IL-2anti-TaclymphocyteSimilarly, the method was well suited to assay inhibition of IL-2-dependent lymphocyte growth by the monoclonal antibody anti-Tac, binding to the human lymphocyte membrane receptor for IL-2.
Pan et al. (1990)interleukin-2interleukin-2An immobilized interleukin-2 receptor which is capable of binding interleukin-2 and suitable for direct N-terminal sequence analysis was employed to study interleukin-2/receptor interactions.
Hofman et al. (1985)interleukin 2anti-Taclymphoid tissueThe monoclonal antibody anti-Tac, which binds to the interleukin 2 (IL 2) receptor, was used to identify this antigen in human fetal and adult lymphoid tissue.
D’Alessandria et al. (2009)HYNIC-IL2unconjugated-IL2cartridgeLanes 1–4 showed the unconjugated-IL2 (lane 1), the HYNIC-IL2 complex after tC2 purification (lane 2), radiolabeled IL2 before (lane 3) and after purification with tC2 cartridge (lane 4).
Duprez et al. (1988)IL2T cellWe have described a human tumor T cell line, IARC 301, which constitutively expresses high affinity interleukin 2 (IL2) receptors, and showed that after binding to its receptors, IL2 is endocytosed and degraded.
Wickremasinghe et al. (1987)Interleukin-2T lymphocytesInterleukin-2 binding to activated human T lymphocytes triggers generation of cyclic AMP but not of inositol phosphates.
Wickremasinghe et al. (1987)IL2lymphocyteWe show here that binding of IL2 to its receptors on the lymphocyte surface triggers the generation of cyclic AMP.
Gillis et al. (1981)TCGFThe impaired response to TCGF was associated with decreased binding of TCGF by PHA-activated cells from old donors.
Kaplan et al. (1988)IL-2These IL-2 epitopes could not be accounted for by soluble IL-2 binding to its specific receptor or adsorbing nonspecifically to the cells.
Sedman et al. (1990)IL-2lymphocytePrompted by two clinical trials which have suggested distinct but apparently opposite effects of lipid emulsions on the production of and lymphocyte responses to IL-2 we have examined the effects of pharmacological concentrations of three lipid emulsions currently in clinical use on IL-2 related interactions in vitro.
Harel-Bellan et al. (1989)IL-2Binding of fluoresceinated IL-2 to different cell types was assessed by flow cytometry analysis, on a FACS 440 calibrated using fluoresceinated Sephadex G-25 beads.
Hall and Wolf (1997)IL-2T cellsBoth ibuprofen and naproxen interfered with the binding of IL-2 to T cells.
Gazzolo and Duc Dodon (1987)IL-2accessory cellsThe mitogenic or antigenic stimulation of T lymphocytes in the presence of accessory cells results in the synthesis of interleukin-2 (IL-2), which, on interacting with de novo synthesized receptors on the membrane, induces the proliferation and differentiation of T cells.
Horst and Flad (1986)IL-2Pharmacological doses of hydrocortisone abolishes both, IL-2 binding and IL-2 response.
Hellstrand and Hermodsson (1989)IL-2monocytesBy interaction with monocytes, interleukin-2 (IL-2) suppressed natural killer (NK) cell cytotoxicity (NKCC) of human, Percoll-fractionated, low-density mononuclear cells.
Wainberg et al. (1984)TCGFThis was shown by allowing known quantities of virus to interact with TCGF activity for different periods of time, followed by centrifugation of any virus-TCGF complexes.